Overview

Oral Sodium Fusidate (CEM-102) Versus Oral Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infections

Status:
Completed

Trial end date:
2016-11-01

Target enrollment:

Participant gender:

Summary

Phase 3, randomized, double-blind, multi-center efficacy and safety study to evaluate an oral CEM-102 loading dose regimen compared to oral linezolid in the treatment of subjects with ABSSSI

Phase:

Phase 3

Details

Lead Sponsor:

Arrevus Inc.
Cempra Inc

Treatments:

Fusidic Acid
Linezolid